Fleeman N, Pilkington G, Dundar Y et al. Allopurinol for the treatment of chronic kidney disease: a systematic review. Health Technol Assess 2014; 18(40): 1-77, v-vi.
Georgianos PI, Tziatzios G, Roumeliotis S et al. Effect of angiotensin converting enzyme inhibitors or angiotensin receptor blockers on cardiovascular outcomes in dialysis patients: a systematic review and meta-analysis. 2022; 38(1): 203-211.
Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2013 Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. 2013.
Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. 2021.
Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (CKD). 2022.
Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD). 2024.
Liang X, Liu X, Li D et al. Effectiveness of Urate-Lowering Therapy for Renal Function in Patients With Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials. Front Pharmacol 2022; 13: 798150.
National Institute for Health and Care Excellence (NICE). Chronic kidney disease: assessment and management (NICE Clinical guidelines; No. 203). 2021.
Palmer SC, Di Micco L, Razavian M et al. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev 2013; (4): CD008834.
Palmer SC, Navaneethan SD, Craig JC et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2014; (5): CD007784.
Sampson AL, Singer RF, Walters GD. Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease. Cochrane Database Syst Rev 2017; (10): CD009460.
Sanguankeo A, Upala S, Cheungpasitporn W et al. Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis. PLoS One 2015; 10(7): e0132970.
Sun L, Zou L, Chen M, Liu B. Meta-analysis of statin therapy in maintenance dialysis patients. Ren Fail 2015; 37(7): 1149-1156.
Taylor KS, McLellan J, Verbakel JY et al. Effects of antihypertensives, lipid-modifying drugs, glycaemic control drugs and sodium bicarbonate on the progression of stages 3 and 4 chronic kidney disease in adults: a systematic review and meta-analysis. BMJ Open 2019; 9(9): e030596.
Tunnicliffe DJ, Palmer SC, Cashmore BA et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2023; 11(11): CD007784.
Xie X, Liu Y, Perkovic V et al. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials. Am J Kidney Dis 2016; 67(5): 728-741.
Zhang L, An K, Mou X et al. Effect of Urate-Lowering Therapy on the Progression of Kidney Function in Patients With Asymptomatic Hyperuricemia: A Systematic Review and Meta-Analysis. Front Pharmacol 2021; 12: 795082.
Zhang Z, Wu P, Zhang J et al. The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: A meta-analysis. Pharmacol Res 2016; 105: 74-83.
IQWiG-Gesundheitsinformationen sollen helfen, Vor- und Nachteile wichtiger Behandlungsmöglichkeiten und Angebote der Gesundheitsversorgung zu verstehen.
Ob eine der von uns beschriebenen Möglichkeiten im Einzelfall tatsächlich sinnvoll ist, kann im Gespräch mit einer Ärztin oder einem Arzt geklärt werden. Gesundheitsinformation.de kann das Gespräch mit Fachleuten unterstützen, aber nicht ersetzen. Wir bieten keine individuelle Beratung.
Unsere Informationen beruhen auf den Ergebnissen hochwertiger Studien. Sie sind von einem Team aus Medizin, Wissenschaft und Redaktion erstellt und von Expertinnen und Experten außerhalb des IQWiG begutachtet. Wie wir unsere Texte erarbeiten und aktuell halten, beschreiben wir ausführlich in unseren Methoden.